COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS

脓毒症中补体依赖性前列腺素合成

基本信息

项目摘要

Although low systemic vascular resistance is a consistent hemodynamic feature of sepsis in humans, relatively little is known about the mechanisms involved. The problem is important, however, because defective regulation of peripheral vasomotor tone is a contributing factor leading to the development of systemic arterial hypotension (i.e., septic shock) in patients with overwhelming infections. Shock remains the single most important predictor of mortality in septic patients. The purpose of this study is to test the hypothesis that decreased vasomotor tone in sepsis is mediated (at least in part) by vasodilating prostaglandins (PGE2 and/or PGI2) and that release of these substances is initiated by activation of the complement system. The studies will employ a rabbit model of endotoxemia that is characterized by low systemic vascular resistance and high cardiac output; i.e., the model satisfactorily replicates the systemic hemodynamic profile of human sepsis. Cardiac output will be measured by thermodilution; regional blood flow will be assessed using radioactive microspheres; plasma levels of metabolites of PGE2 and PGI2 will be determined by radioimmunoassay. Three series of experiments will be conducted. The first will examine the effect of pharmacologically limiting the formation of prostaglandins or complement-derived peptides on systemic and regional hemodynamics and plasma prostaglandin levels in endotoxic rabbits. Prostaglandin synthesis will be inhibited by administering meclofenamate or ibuprofen; formation of complement-derived peptides will be inhibited by prior decomplementation with cobra venom factor or treatment with inhibitors of complement activation. The second series of experiments will investigate systemic and regional hemodynamics and plasma prostaglandin levels in rabbits infused with graded doses of either zymosan- activated plasma (a source of complement-derived peptides) or cobra venom factor (to initiate the formation of these peptides in vivo). The studies will be performed in the presence and absence of PG synthesis inhibitors. The third series of experiments will ascertain whether the hemodynamic effects of vasodilating doses of endotoxin or activated complement depend upon interaction with polymorphonuclear leukocytes. These studies should provide important new insights into the mechanisms underlying the derangements in vasomotor tone in sepsis and possibly lead to improved therapeutic strategies.
虽然低全身血管阻力是一致的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mitchell P. Fink其他文献

Effects of nonsteroidal anti-inflammatory drugs on renal function in septic dogs.
非甾体抗炎药对脓毒症犬肾功能的影响。
  • DOI:
    10.1016/0022-4804(84)90135-5
  • 发表时间:
    1984
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mitchell P. Fink;Thomas J. MacVittie;Larry C. Casey
  • 通讯作者:
    Larry C. Casey
Postoperative complications in patients with disabling psychiatric illnesses or intellectual handicaps. A case-controlled, retrospective analysis.
患有致残性精神疾病或智力障碍的患者的术后并发症。
  • DOI:
    10.1001/archsurg.1990.01410230030005
  • 发表时间:
    1990
  • 期刊:
  • 影响因子:
    0
  • 作者:
    B. Cutler;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
Biology of heterotrimeric G-protein signaling.
异源三聚体 G 蛋白信号传导生物学。
  • DOI:
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    R. Forse;John M. Luce;Michael B. Yaffe;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
Hemorrhagic Ascites: An Unusual Presentation of Primary Splenic Lymphoma
  • DOI:
    10.1016/s0016-5085(82)80346-6
  • 发表时间:
    1982-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Joseph F. Hacker;Joel E. Richter;Robert S. Pyatt;Mitchell P. Fink
  • 通讯作者:
    Mitchell P. Fink
CRISIS IN CRITICAL CARE The Demand for Critical Care Services is Increasing Critical care
重症监护危机 对重症监护服务的需求正在增加 重症监护
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    David T. Huang;T. Osborn;K. Gunnerson;Scott R. Gunn;Stephen Trzeciak;Edward Kimball;Mitchell P. Fink;De Angus;R. Dellinger;Emanuel P. Rivers
  • 通讯作者:
    Emanuel P. Rivers

Mitchell P. Fink的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mitchell P. Fink', 18)}}的其他基金

MOLECULAR BASIS FOR EPITHELIAL BARRIER DYSFUNCTION/PROJECT 2
上皮屏障功能障碍的分子基础/项目 2
  • 批准号:
    6829217
  • 财政年份:
    2004
  • 资助金额:
    $ 5.57万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6765286
  • 财政年份:
    2003
  • 资助金额:
    $ 5.57万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6911508
  • 财政年份:
    2003
  • 资助金额:
    $ 5.57万
  • 项目类别:
Ethyl Pyruvate: A Novel Treatment for Sepsis
丙酮酸乙酯:脓毒症的新型治疗方法
  • 批准号:
    6669337
  • 财政年份:
    2003
  • 资助金额:
    $ 5.57万
  • 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
  • 批准号:
    3466035
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2684840
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2178852
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
  • 批准号:
    3466034
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    2178851
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:
INTESTINAL PERFUSION AND PERMEABILITY IN SEPSIS
脓毒症的肠道灌注和渗透性
  • 批准号:
    6197428
  • 财政年份:
    1987
  • 资助金额:
    $ 5.57万
  • 项目类别:

相似海外基金

Complement inhibitors targeted to the ischemic brain for the treatment of stroke
针对缺血性大脑的补体抑制剂用于治疗中风
  • 批准号:
    9316844
  • 财政年份:
    2017
  • 资助金额:
    $ 5.57万
  • 项目类别:
Role of complement factor MASP-1/3 in age-related macular degeneration and therapeutic effect of novel complement inhibitors
补体因子MASP-1/3在年龄相关性黄斑变性中的作用及新型补体抑制剂的治疗效果
  • 批准号:
    17K16975
  • 财政年份:
    2017
  • 资助金额:
    $ 5.57万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Complement inhibitors for treatment of chronic inflammatory diseases
用于治疗慢性炎症性疾病的补体抑制剂
  • 批准号:
    nhmrc : 1082090
  • 财政年份:
    2015
  • 资助金额:
    $ 5.57万
  • 项目类别:
    Project Grants
Complement inhibitors for treatment of chronic inflammatory diseases
用于治疗慢性炎症性疾病的补体抑制剂
  • 批准号:
    nhmrc : GNT1082090
  • 财政年份:
    2015
  • 资助金额:
    $ 5.57万
  • 项目类别:
    Project Grants
Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
  • 批准号:
    8730337
  • 财政年份:
    2013
  • 资助金额:
    $ 5.57万
  • 项目类别:
Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
  • 批准号:
    8701429
  • 财政年份:
    2013
  • 资助金额:
    $ 5.57万
  • 项目类别:
Scabies mite complement inhibitors as targets for novel therapeutics
疥螨补体抑制剂作为新疗法的靶点
  • 批准号:
    nhmrc : 1054968
  • 财政年份:
    2013
  • 资助金额:
    $ 5.57万
  • 项目类别:
    Early Career Fellowships
Complement Inhibitors as DMOADs
作为 DMOAD 的补体抑制剂
  • 批准号:
    8252300
  • 财政年份:
    2012
  • 资助金额:
    $ 5.57万
  • 项目类别:
N. Meningitidis-inspired stealthiness: Prolonging the circulation times of anticancer nanocarriers by scavenging endogenous complement-inhibitors.
脑膜炎奈瑟氏球菌启发的隐秘性:通过清除内源性补体抑制剂来延长抗癌纳米载体的循环时间。
  • 批准号:
    214146
  • 财政年份:
    2010
  • 资助金额:
    $ 5.57万
  • 项目类别:
    Fellowship Programs
Complement Inhibitors for Macular Degeneration
黄斑变性的补体抑制剂
  • 批准号:
    8824604
  • 财政年份:
    2009
  • 资助金额:
    $ 5.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了